In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Aduro Biotech, Inc.. Trade Record

NASDAQ:ADRO Aduro Biotech, Inc. stock gains 16.11% Exit Sep 11, 2018 a Trade Record by priceseries

Trade Chart
Trade Chart ADRO Aug 24, 2018, priceSeries
About Aduro Biotech, Inc.

Aduro BioTech, Inc., an immunotherapy company, focuses on the discovery, development, and commercialization that transform the treatment of challenging diseases. It is developing CRS-207, which has completed Phase Ib clinical trials for the treatment of unresectable malignant pleural mesothelioma; that has completed Phase II clinical trials for the treatment of pancreatic cancer; and that is in Phase I/II clinical trials for the treatment of ovarian cancer. The company is also developing ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; ADU-741, which is in Phase I clinical trials for the treatment of prostate cancer; and a product candidate for the treatment of patients with cancers of the gastrointestinal tract. In addition, it is developing STING Pathway Activator product candidates that are synthetic small molecule immune modulators, which target and activate Stimulator of Interferon Genes receptor under collaboration with Novartis Pharmaceuticals Corporation; and product candidates that address other therapeutic areas, such as autoimmune and infectious diseases. Further, the company's products pipeline comprises BION-1301, a B-select mAb novel therapy for multiple myeloma; and antibody product candidates, including APRIL for the treatment of multiple myeloma, as well as oncology therapies, such as CD27, PD-1, and CTLA-4. Aduro BioTech, Inc. has a collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers; and development and commercialization agreement with Genmab to evaluate five bispecific antibody product candidates targeting immune checkpoints. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is headquartered in Berkeley, California.

Trade Information
Trade Type
Entry Date
Aug 24, 2018
Entry Price
Sell Date
Sep 11, 2018
Sell Price
Net Gain
Hold Time
11 Trading Days